Alcobra Ltd. is planning to raise $15 million in its IPO.
Cynapsus Therapeutics Inc. is offering units for aggregate proceeds of $5.9 million.
Enanta Pharmaceuticals Inc. priced a $56 million IPO.
GW Pharma plc has filed for a listing on Nasdaq, with the goal of raising up to $50 million.
Rockwell Medical Inc. is selling 4.3 million common shares at $3 per share in a registered direct offering.
Savara Pharmaceuticals Inc. closed a $7.4 million second tranche of a Series B financing.
Stem Cell Therapeutics Corp. closed its offering of units for aggregate gross proceeds of $3.1 million.
Tetraphase Pharmaceuticals Inc. priced its IPO raising $75 million.
BGI-Shenzhen completed the acquisition of Complete Genomics Inc.
Cancer Research Technology and the Institute of Cancer Research are collaborating with Janssen Biotech Inc.
UCB SA and Five Prime Therapeutics Inc. are collaborating on inflammatory diseases and CNS disorders.
. . . And More
Affymax Inc. has cut 230 employees and it examining its strategic alternatives.
AstraZeneca plc plans to relocate 2,500 positions and cut about 1,600 jobs, mainly in the UK and U.S.
Quest Diagnostics Inc. has developed a clinical test panel to aid the diagnosis of suspected dementia.
ThromboGenics NV received a $58.8 million milestone payment from its partner, Alcon.
Vanda Pharmaceuticals Inc. withdrew its European MAA for Fanaptum for the treatment of schizophrenia.